comparemela.com

Latest Breaking News On - Helen tuvesson - Page 1 : comparemela.com

Investegate |Active Biotech Announcements | Active Biotech: Active Biotech strengthens the patent protection for laquinimod in eye disorders

Investegate announcements from Active Biotech, Active Biotech strengthens the patent protection for laquinimod in eye disorders

Hans kolamHelen tuvessonEuropean patent officeUs patent officeActive biotechInvestegate announcementsInvestegate company announcementsActive biotechLobenewswire and globenewswire

Active Biotech strengthens the patent protection for laquinimod in eye disorders

Lund, April 26, 2022, Active Biotech (NASDAQ STOCKHOLM: ACTI) today announced that the European Patent Office (EPO) has issued a decision to grant Active Biotech's patent related to use of laquinimod as

Hans kolamHelen tuvessonEuropean patent officeUs patent officeActive biotech

Active Biotech Appoints Erik Vahtola as Chief Medical Officer

Lund, January 4, 2022 - Active Biotech (NASDAQ STOCKHOLM: ACTI) announced today that Dr. Erik Vahtola, MD, PhD, has been appointed Chief Medical Officer (CMO), effective January 1, 2022. He will join the

Eteläuomen läiHans kolamHelena erikssonErik vahtolaHelen tuvessonRoche pharmaBayer pharmaceuticalsAkademi universityHelsinki university central hospitalOrion corporationChief medical officerActive biotechMedical doctor

vimarsana © 2020. All Rights Reserved.